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Non-human primates are considered to be likely sources of viruses that can infect humans and thus
pose a signiﬁcant threat to human population. This is well illustrated by some retroviruses, as the
simian immunodeﬁciency viruses and the simian T lymphotropic viruses, which have the ability to
cross-species, adapt to a new host and sometimes spread. This leads to a pandemic situation for HIV-1
or an endemic one for HTLV-1. Here, we present the available data on the discovery, epidemiology,
cross-species transmission and molecular virology of the recently discovered HTLV-3 and HTLV-4
deltaretroviruses, as well as the simian foamy retroviruses present in different human populations at
risk, especially in central African hunters. We discuss also the natural history in humans of these
retroviruses of zoonotic origin (magnitude and geographical distribution, possible inter-human
transmission). In Central Africa, the increase of the bushmeat trade during the last decades has opened
new possibilities for retroviral emergence in humans, especially in immuno-compromised persons.
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A large proportion of viral pathogens that have emerged during
the last decades in humans are considered to have originated from
various animal species (Weber and Rutala, 1999; Wolfe et al., 2007).
This is well exempliﬁed by several recent epidemics such as those of
Nipah, Severe Acute Respiratory Syndrome, avian ﬂu, Ebola, monkey
pox, and Hanta viruses (Flanagan et al., 2012).
When considering the huge diversity of animal reservoirs and
the variety of factors leading to animal/human contacts followed
by viral cross-species transmission, one can hypothesize that the
emergence of new viruses of zoonotic origin is very probable, if
not ineluctable. However, anticipating the species jumps, identi-
fying high-risk viruses before they emerge in humans, and
predicting when, how and with which magnitude such events
can occur remains extremely difﬁcult (Flanagan et al., 2012).
Indeed, emergence of a viral disease in Humans results from the
succession of various events, often complex, implying several factors.
Each of these steps, and of the associated factors, (of viral, host,
environmental or socio-cultural origin) is crucial for the emergence
success. Fortunately, the absolute necessity for a perfect connection
between these different items may explain the relative rarity of viral
emergence in Humans.
After the initial interspecies transmission per se, viruses dissemi-
nated into the human population through various and distinct
mechanisms. Some of them are well characterized and understood,
thus allowing a certain level of risk control and prevention. Surpris-
ingly and in contrast, the initial steps that lead to the emergence of
several viruses, and of their associated diseases, remain still poorly
understood. Epidemiological ﬁeld studies conducted in certain spe-
ciﬁc high-risk populations are thus necessary to obtain new insights
into the early events of this emergence process (Parrish et al., 2008).
Human infections by simian viruses represent increasing public
health concerns. Indeed, by virtue of their genetic and physiological
similarities, non-human primates (NHPs) are considered to be likely
the sources of viruses that can infect humans and thus may pose a
signiﬁcant threat to human population. This is well illustrated by
retroviruses, which have the ability to cross species, adapt to a new
host and sometimes spread within this new species (Locatelli and
Peeters, 2012). Sequence comparison and phylogenetic studies have
thus clearly showed that the emergence of human immunodeﬁ-
ciency virus type 1 (HIV-1) and HIV-2 in humans have resulted from
several independent interspecies transmissions of different SIV types
from Chimpanzees and African monkeys (including sooty manga-
beys), respectively, probably during the ﬁrst part of the last century
(Aghokeng et al., 2006; Hahn et al., 2000; Plantier et al., 2009; Van
Heuverswyn et al., 2006; Van Heuverswyn and Peeters, 2007). The
situation for Human T cell Lymphotropic virus type 1 (HTLV-1) is, for
certain aspects, quite comparable. Indeed, the origin of most HTLV-1
subtypes appears to be linked to interspecies transmission between
STLV-1-infected monkeys and humans, followed by variable periods
of evolution in the human host. Gessain and Mahieux (2000),
Nerrienet et al. (2001), Sintasath et al. (2009a), Wolfe et al. (2005).
In this review, we will present the current available data on the
discovery, cross-species transmission from monkeys and apes to
humans, and molecular virology of the recently discovered HTLV-3
and HTLV-4 retroviruses, as well as on simian foamy retrovirusespresent in different human populations at risk, especially in central
African hunters.HTLV-3/HTLV-4 and related simian retroviruses
Human T Lymphotropic Viruses (HTLV-1, HTLV-2 and HTLV-3) as
well as their related simian counterparts (STLV-1, STLV-2 and STLV-
3) constitute the Primate T-cell Lymphotropic viruses (PTLV) group
(Lairmore and Franchini, 2007). These different deltaretroviruses
share several epidemiological and molecular characteristics. While
PTLV-1 and PTLV-2 strains have been extensively studied since the
80’s, studies on PTLV-3 are more recent but their number increased
after the discovery of HTLV-3 in 2005 (Calattini et al., 2005; Wolfe
et al., 2005). HTLV-4, the fourth HTLV retrovirus was also discovered
in 2005, but a simian counterpart of this virus has not been
identiﬁed to date (Sintasath et al., 2009a; Wolfe et al., 2005).STLV-3/HTLV-3 discovery and epidemiological characteristics
The ﬁrst STLV-3 strain (STLV-L/PH-969) was isolated in 1994, after
co-culture of human cord blood lymphocytes with peripheral blood
mononuclear cells (PBMCs) obtained from an Eritrean sacred baboon
(Papio hamadryas) kept in captivity in a research laboratory in Leuven
(Belgium) (Goubau et al., 1994). Sequencing of this virus, considered
as the third lineage of the PTLV group and labeled thus as STLV-3,
revealed a signiﬁcant nucleotide divergence when compared to
HTLV-1 and HTLV-2 prototypical sequences (40% and 38%, respec-
tively). From December 2001, a series of other STLV-3 strains
were then described. Those strains were Polymerase Chain Reac-
tion (PCR)-ampliﬁed from the PBMCs of different monkey species,
originating from West, Central and East Africa. Some of these
STLV-3 viruses were present in wild-caught and/or wild-
born animals living in Cameroon, Nigeria or Ethiopia, while
other monkeys had been kept in captivity either in France in an
ethological center, or in US zoos (Courgnaud et al., 2004; Meertens
and Gessain, 2003; Meertens et al., 2002, 2003; Takemura et al.,
2002; Van Dooren et al., 2001, 2004). Most STLV-3 serologies
resembled an HTLV-2 pattern (gag-p244gag-p19 and env-gp21
GD21, þ/ env-gp46 K55) when determined with an HTLV-1/2
commercial western-blot assay (HTLV2-4 WB GenLabs) and/or
with other assays (INNOLIA) (Courgnaud et al., 2004; Meertens
and Gessain, 2003; Meertens et al., 2002; Van Dooren et al., 2004).
Very few data are available on the epidemiological determinants
(i.e., age, sex, modes of transmissions) of STLV-3 infection within
infected non-human primates (NHP) as to date, most studies
were performed in wild-caught monkeys (Courgnaud et al., 2004;
Liegeois et al., 2008; Sintasath et al., 2009a; 2009b; Takemura et al.,
2002). STLV-3 prevalence varies greatly according to the NHP
species, the geographical location and the methodologies used for
animals sampling (living monkeys kept as pets in villages, dead
animals with bushmeat samples collection of blood or of dried
blood spots), but STLV-3 infection has not been linked to any
pathology so far. STLV-1 and STLV-3 can be found in the same
primate species and even in the same animal (Courgnaud et al.,
2004; Liegeois et al., 2008; Sintasath et al., 2009a). Based on partial
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to be composed of four main subtypes (A–D) that roughly corre-
spond to the geographical source of the strains. Subtype A
comprises strains from East Africa (Ethiopia and Eritrea), subtype
B corresponds to strains from West and Central Africa, while the
subtypes C and D comprise strains from Central Africa. Therefore,
and although STLV-3 genome can be edited by double-stranded
RNA adenosine deaminase (Ko et al., 2012), its variability remains
low as it is the case for other PTLVs.
In 2005, we and others reported the discovery of HTLV-3, a
third HTLV type, in two asymptomatic individuals living in the
rain forest area of South Cameroon (Calattini et al., 2005; Wolfe
et al., 2005). Sera from those individuals exhibited HTLV indeter-
minate serologies when tested with commercial western-blot
assays. These two viruses could not be isolated in culture, but
the proviruses were PCR-ampliﬁed using a series of primers
designed to amplify all known HTLVs and STLVs. More recently,
the same teams reported the discovery of two additional HTLV-3
strains in other individuals (Lobak18 and Cam 2013AB) from
Cameroon (Calattini et al., 2009; Zheng et al., 2010).HTLV-4, another retrovirus found in humans
The fourth HTLV type (HTLV-4) consists so far of a unique human
strain (1863LE), whose provirus was also found in the PBMCs
obtained from a hunter living in Cameroon (Wolfe et al., 2005).
The WB proﬁle was also classiﬁed as HTLV-indeterminate. Phyloge-
netic studies indicated that HTLV-4 constituted clearly a monophy-
letic viral group and is considered as the oldest PTLV known-lineage
(Switzer et al., 2009). Its sequence is equidistant from HTLV-1,
HTLV-2 and HTLV-3, sharing only 62–71% nucleotide identity with
them, respectively. Given previous epidemiological data on PTLV-1
and PTLV-3, it is likely that a monkey species is infected or has been
infected with the simian counterpart of HTLV-4. However, despite
screening of a large number of monkey species from Cameroon,
Gabon and Democratic Republic of Congo, the search for such a virus
has been unsuccessful up to now (Ahuka-Mundeke et al., 2012;
Liegeois et al., 2012, 2008; Sintasath et al., 2009a, 2009b).Molecular virology
HTLV-3 and HTLV-4 genomic organization
The prototype HTLV-4 proviral sequence (1863LE) is 8791-bp
long (Switzer et al., 2009; Wolfe et al., 2005), while that of HTLV-3
(Pyl43) is 8553-bp long but contains a 366-bp deletion (Calattini
et al., 2006a). Other HTLV-3 sequences are larger (8922-bp long
for Lobak18, 8917-bp for 2026ND and 8913-bp for Cam2013AB)
(Calattini et al., 2009; Switzer et al., 2006; Zheng et al., 2010). The
overall HTLV-3 and HTLV-4 genomic organization is similar to
that of other retroviruses with the presence of gag, pro, pol and
env Open Reading Frames (ORF) encoding for structural and
enzymatic proteins from non-spliced or singly-spliced mRNAs.
As other HTLVs which belong to the complex retroviruses family,
the provirus also contains additional ORFs: tax and rex on the sense
strand and the Antisense Protein of HTLV-3 (APH-3) or of HTLV-4
(APH-4) ORFs on the antisense strand (Larocque et al., 2011) (Fig. 1).
The presence of additional ORFs that would encode for auxiliary
proteins is the subject of current investigations (see below). HTLV-
3/-4 proviral DNA sequence is ﬂanked by two complete Long
Terminal Repeat (LTR) sequences. Contrary to HTLV-1 and HTLV-2
50LTR that contains three 21-bp repeats sequences (also name
Tax Responsive Elements), HTLV-3/-4 50LTRs contain two of those
motifs (Calattini et al., 2006a; Switzer et al., 2006, 2009). Theycorrespond to transcription factor binding sites, where the RNA
PolymeraseII complex will be recruited through Tax interaction.
A c-Myb binding site is also present in HTLV-4 50LTR (Switzer
et al., 2009). HTLV-3/-4 30LTRs also contain a promoter whose
regulation is currently unknown and that allows transcription of
aph-3/4 mRNAs (Larocque et al., 2011).
Due to the lack of HTLV-3 or HTLV-4 transformed cell lines,
most results described below have been obtained either in vitro,
after transfection of plasmids encoding different isolated proteins,
or thanks to the use of HTLV-3 or HTLV-4 infectious molecular
clones (Chevalier et al., 2008, 2007; Larocque et al., 2011).
HTLV-3/-4 cell entry
HTLV-3/-4 tropism in vivo is currently unknown, yet it is clear
that the virus infects at least cells that belong to PBMCs. As HTLV-
1/-2, which, in addition to dendritic cells, infect activated CD4þ
and CD8þ T cells, respectively in vivo, we have shown that HTLV-3
surface envelope glycoprotein (gp46 or SU) binds to both activated
CD4þ and CD8þ T, but also to naı¨ve CD4þ T cells (Jones et al.,
2009). The latter do not bind HTLV-1 or HTLV-2 SU and do not
express detectable levels of heparan sulfate proteoglycans (HSPGs),
neuropilin-1 (NRP-1) and Glucose transporter 1 (GLUT-1). A series
of experiments also demonstrated that GLUT-1 serves at a post-
binding step factor for HTLV-3. These results indicate that the
complex of molecules used by HTLV-3 to bind and enter into
CD4þ and CD8þ T lymphocytes in vitro differs from that of HTLV-
1 and HTLV-2 (Fig. 2). Ongoing experiments are currently being
performed using blood samples from STLV-3 infected animals and
should allow the determination of PTLV-3 tropism in vivo in non-
human primate cells.
Characterization of Tax-3/-4 proteins
Since Tax is both a viral transactivator and a viral oncogene,
most experiments were aimed at characterizing the function of
this protein. As in a subset of HTLV-1 carriers, HTLV-3 Tax (Tax-3)
protein is expressed in vivo and allows an antibody response
(Chevalier et al., 2006), while data are not available for Tax-4.
Tax-3 sequence shares a number of key similarities with Tax-1,
including the presence of a putative Nuclear Localization Signal
(NLS), a functional CBP/p300 binding domain, a Nuclear Export
Signal, a CR2 binding domain and a PDZ binding motif (PBM)
(Chevalier et al., 2006). Importantly, this latter sequence is critical
for the ability of the Tax-1 protein to transform cells in vitro. In vitro
analyses showed that, as Tax-2, HTLV-4 Tax protein lacks a PBM but
contains the other domains (Switzer et al., 2009).
When ectopically expressed, Tax-3 displays a strong nuclear
localization with some cytoplasmic speckles. In addition to its
ability to transactivate the 50LTR, Tax-3 also activates the NF-kB
pathway (Chevalier et al., 2008). A series of experiments was
recently performed to compare the global gene expression proﬁle
of cells expressing Tax-1, Tax-2 and Tax-3. This led to the conﬁrma-
tion that Tax-3 was functionally analogue to Tax-1 (Chevalier et al.,
2012). Functional data are not available for Tax-4.
HTLV-3 and HTLV-4 putative auxiliary proteins
HTLV-1 encodes 4 different auxiliary proteins: p13, p30, p12 and
p8 which results from a proteolytic cleavage of p12 (for a recent
review, see (Edwards et al., 2011). Those proteins play important
roles in HTLV-1 infected cells: p30, notably promotes viral latency
by decreasing expression of the viral transcription transactivator
Tax, and in turn, favors viral persistence and escape from the
immune system (Nicot et al., 2004). p12 mediates cell proliferation
and differentiation by activating STAT-5 signaling (Collins et al.,
Fig. 1. Schematic representation of PTLV-1, -2, -3 and -4 genomic organization and coding potential. PTLVs are complex retroviruses displaying a conserved genomic
arrangement. Grey: colored boxes indicating Open Reading Frame (ORF) encoding structural and enzymatic proteins (gag, pro, pol and env); Red: ORF encoding regulatory
proteins (Tax, Rex, sHBZ (HTLV-1), APH-2, -3 and -4 (HTLV-2, -3 and -4, respectively)). Blue: ORF encoding auxiliary proteins: p8/p12, p13, p30 for HTLV-1; p10, p11, p28 for
HTLV-2 and p8, p9, RoRFII for PTLV-3. The presence of ORFs encoding auxiliary proteins in HTLV-4 sequence was reported from in silico analyses only.
A. Gessain et al. / Virology 435 (2013) 187–1991901999). p12 also promotes escape from immune surveillance by
reducing the activation of CTLs and NK cells (Banerjee et al., 2007).
p8, promotes conjugate formation and favors HTLV-1 transmission
(Van Prooyen et al., 2010). Finally, p13 increases mitochondrial ROS
(Reactive Oxygen Species) production, thus altering cell fate and
thus favoring bypass of the immune surveillance (Silic-Benussi
et al., 2010). p13 may also promote viral latency and favors viral
persistence (Andresen et al., 2011).
As HTLV-1/-2 genomes, the sequence located downstream the
HTLV-3/–STLV-3 or HTLV-4 env gene (named pX) contains several
ORFs (open reading frames) encoding putative auxiliary proteins.Those proteins would be translated after complex splicing of their
respective mRNAs. The presence of a doubly spliced mRNA that
would encode a 85 amino acid highly hydrophobic and leucine
rich protein named RorfII was reported several years ago in STLV-3
infected cells (Van Brussel et al., 1996). More recently, two other
mRNAs that would encode a 63 and a 79 amino acid long proteins
named p8 and p9, respectively were also ampliﬁed from STLV-3
infected cells (Turpin et al., 2011). Their function is currently under
characterization.
Regarding HTLV-3, the presence of additional mRNAs has
only been predicted for some strains after in silico analyses. A ﬁrst
HTLV-3
HTLV-1
HTLV-2
HTLV-1,2
= HSPG
= NRP-1
= GLUT-1activated
activated
non activated
T-cell
T-cell
T-cell
+
+
-
+
+
+
Fig. 2. Schematic representation of HTLV-1, -2 and -3, receptor complexes on T
cells. HTLV-1 binding and entry require the presence of heparan sulphate
proteoglycans (HSPGs), Neuropilin 1 (NRP-1) and glucose transporter type 1
(GLUT-1) on the surface of activated CD4þ cells. On the other hand HTLV-2
preferentially targets CD8þ cells and is more dependent on the level of GLUT-1
and does not require HSPGs. Unlike HTLV-1 and HTLV-2, HTLV-3 binds to primary
resting cells that do not express detectable levels of HSPGs, NRP-1 or GLUT-1. GLUT-1
may participate in the ﬁnal fusion step of entry (Jones et al., 2011). : cells cannot be
infected, þ: cells can be infected. Figure was made using Servier Medical Art.
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122, 72 and 118 amino acid long proteins in 2026ND proviral
sequence (Switzer et al., 2006). Surprisingly, only one ORF encod-
ing a putative 131 amino acid long protein named ORF-I and
previously reported for a STLV-3 sequence (Sintasath et al., 2009b)
is present in Cam2013AB (both viruses belonging to subtype D) pX
sequence (Zheng et al., 2010), while the presence of additional
ORFs was not reported for Lobak18 or Pyl43.
In silico analyses conducted on HTLV-41863LE genome provirus
revealed the presence of ﬁve putative ORFs that might encode
proteins of 101, 161, 99, 133 and 115 amino-acids (Switzer et al.,
2009). However, none of those ORFs starts with a methionine
codon. Thanks to the construction of an HTLV-4 molecular clone,
investigating whether those mRNAs are truly present in infected
cells should be tested.
Antisense protein of HTLV-3 and HTLV-4
As described above, and as it is the case for all HTLVs, HTLV-3
and HTLV-4 proviruses encode antisense proteins (APH-3 and
APH-4, respectively). Transcription of their respective mRNAs
starts at different initiation sites. Both proteins were recently
characterized from cells transfected with molecular clones
(Larocque et al., 2011). APH-3 and APH-4 are 221 (28 kDa) and
158 (18 kDa) amino acid long, respectively and are translated from
spliced mRNAs. Contrary to HBZ (Gaudray et al., 2002) and as their
APH-2 HTLV-2 homologue (Halin et al., 2009), their sequence is
devoid of a classical basic leucine zipper. It contains however
LXXLL and LXXLL-like motifs that could allow binding to CBP/
p300. In silico analyses suggest that APH-3 and APH-4 are more
closely related to APH-2 than to HBZ (Larocque et al., 2011).
However, in transfected cells, both proteins are localized into the
cell nucleus and nucleolus, APH-3 being also partially detected
in the cytoplasm (Larocque et al., 2011). Surprisingly, this locali-
zation is more similar to that of HBZ than to APH-2. As their
HTLV-1 and HTLV-2 counterparts, both APH-3 and APH-4 repress
transcription from the HTLV-1 50LTR (Larocque et al., 2011).
Whether APH-3 and APH-4 are widely expressed in vivo, such as
their HTLV-1 and HTLV-2 counterparts (Douceron et al., 2012;
Satou et al., 2006) remains to be determined.Simian foamy viruses in humans
History
The ﬁrst foamy virus was described in rhesus monkey kidney
cells in 1954 (Enders and Peebles, 1954). Since then, foamy viruses
have been isolated from many different animal species, including
bovines, felines and equines and several non-human primate species
(Meiering and Linial, 2001; Murray and Linial, 2006; Saib, 2003;
Winkler et al., 1999). The prevalence of FVs in naturally infected
animals is generally high, but can vary widely according to species
and environmental conditions. Several epidemiological studies indi-
cated that, among captive NHP populations (Blewett et al., 2000;
Calattini et al., 2004; Hussain et al., 2003; Schweizer et al., 1999,
1995), but also in free-range colonies (Calattini et al., 2006c;
Mouinga-Ondeme et al., 2010) and in the wild (Jones-Engel et al.,
2005; Leendertz et al., 2010; Liu et al., 2008), SFV seroprevalence can
reach up to 75–100% in adults, but is generally much lower in infants
and juveniles (Liu et al., 2008). SFV virions are present at a high
concentration in the saliva of infected NHPs (from 104 to 109 FV RNA
copies/104 cells equivalent). In African green monkey and macaques
NHPs, oral mucosa tissue is indeed an important site for viral
replication (Falcone et al., 1999; Murray et al., 2008, 2006). These
results, as well as epidemiological studies and long-term behavioral
observations, strongly suggest a saliva-based means of transmission
such as bites, licking, and mucosal splashes (Calattini et al., 2006c;
Leendertz et al., 2010). The infection by SFV does not seem to cause
any disease in infected NHPs, but speciﬁc studies have not been
conducted to adress this question.
Foamy viruses in humans
The ﬁrst foamy virus to be isolated in humans was reported by
Achong et al., in 1971 from the cell culture of a Kenyan patient
suffering of nasopharyngeal carcinoma (Achong et al., 1971).
Recent phylogenetic studies demonstrated that this virus origi-
nated from the East African chimpanzee subspecies (Pan
t. Schweinfurtii). This virus has now been renamed as the ‘‘proto-
type foamy virus’’, PFV. However, it remains unclear whether this
ﬁrst ‘‘human’’ foamy isolate arose from an in vivo cross-species
transmission from a chimpanzee to the African carrier, or if it
originated from a cell culture contamination.
During the 70’s/80’s, several laboratories tried to demonstrate
the existence of other sporadic cases of FV infected persons but
also to search for human populations where such virus could be
endemic. Results were contrasted. Whereas several serological
studies provided evidence for FV in different populations, other
groups mainly found negative results. (reviewed in (Meiering and
Linial, 2001)). Such discrepancies reﬂected the high percentage of
non-speciﬁc serological reactivities and the lack of speciﬁc con-
ﬁrmatory test at that time. Indeed, when SFV-speciﬁc serological
(western blot (WB), radio-immunoprecipitation (RIPA), speciﬁc IF)
and molecular assays (PCR) were available, most of the positive
results obtained previously in different human populations, as well
as in several series of patients (neurological disorders, cancers,
thyroiditis, inﬂammatory diseases), were not conﬁrmed (Meiering
and Linial, 2001).
Those studies also lead to the discovery that some persons
working directly with NHPs were truly infected by SFVs. The ﬁrst
clear evidence of SFV in Humans was shown in 1995 among
3 laboratory and monkey house personnels at risk for acquiring
simian viruses (Schweizer et al., 1995) (Table 1). After these initial
studies, a Center for Diseases Control (CDC) team demonstrated
that, some workers occupationally exposed to NHPs were SFV
infected (Heneine et al., 1998). Another study demonstrated the
presence of SFV infection in workers from a primate facility in
Table 1
Epidemiological data of SFV-infected persons being occupationally exposed to NHP.
Country Number of cases Sex M/F Risk factors Reported injuries Viral strain References
Germany 3/41 NA Animal caretaker Bites AGM Schweizer et al. (1997, 1995)
North America
(USA and Canada)
4/231 4/0 Animal caretaker
Research scientist
Animal care supervisor
Veterinarian
Bites (3) AGM (1)
Baboon (3)
Heneine et al. (1998)
North America 4/133a NA Zoo keepers NA NA Sandstrom et al. (2000)
Canada 2/46b NA Primate facility workers Bites Macaques (1) Brooks et al. (2002)
North America 10/187c 8/2 Animal caretaker (4)
Veterinarian (3)
Animal care supervisor (1)
Technician (2)
Bites (4)
Scratches (2)
None (2)
Others (2)
Chimps (8)
Baboon (1)
Switzer et al., 2004
Gabon 2/20 2/0 Veterinarian (1)
Technician (1)
Bites (2) Mandrill (1) Macaque(1) Mouinga-Ondeme et al. (2010)
China (Yunnan) 2/12 NA Zookeepers Bite, Spit (2) Macaques (2) Huang et al. (2012)
NA Not available.
a Presence of SFV infection was based only on speciﬁc seropositivity.
b PCR was found positive in the PBMCs of 1/2 seropositive individuals.
c PCR was found positive in the PBMCs of 9/10 seropositive individuals.
Table 2
Epidemiological data of SFV-infected persons being exposed to NHP in natural settings.
Country Number
of cases
Sex
M/F
Risk factors Reported injuries Viral strain References
Cameroon 3/1099 2/1 Individuals reporting direct
contact
with NHP blood and/or body
ﬂuids
Hunting Butchering Pets Mandrill (1)
Cercopithecus (1)
Gorilla (1)
Wolfe et al. (2004)
Indonesia 1/82 1/0 Monkey temple workers Bites Scratches Macaques Jones-Engel et al.
(2005)
Cameroon 4/1164 3/1 General adult population from
villages located close to
NHP habitats
Bites (3)
None (1)
Gorilla (3)
Chimp (1)
Calattini et al. (2007)
9/85 9/0 Individuals reporting direct
contact with NHPs (bites,
scratches, wounds, etc.)
Bites (9) Gorilla (5)
Chimps (2)
Mandrill (1)
Cercopithecus (1)
South and Southeast
Asia countries
(Thailand, Indonesia, Nepal,
Bangladesh)
3/305 1/2 Monkey temple workers
Villagers Pet owners
Bites (3) Macaques :
Macaca fascicularis (2)
Macaca mulatta (1)
Jones-Engel et al.
(2008)
Cameroon 1/35 1/0 Pygmies (Hunters, Butchers) Bite (1) Chimpanzee Calattini et al. (2011)
Cameroon 2/1321 1/1 General adult population from
villages
located close to NHP habitats
None (2) Gorilla (1)
Cercopithecus (1)
Betsem et al. (2011)
37/98 37/0 Individuals reporting direct
contact with NHPs (bites,
scratches, wounds, etc.)
Bites (37) Gorilla (31)
Chimps (3)
Cercopithecus (3)
Gabon 15/78 15/0 Villagers with bites or
scratches (Hunting/ Pet)
Bites (15) Gorilla Chimps
Cercopithecus
Mouinga-Ondeme et al.
(2012)
DRC 3/3334 0/3 Villagers Butchers preparing monkey
to eat (2)
None (1)
Angolan Colobus
Red Tail monkey
Switzer (in press)
Only persons with SFV infection demonstrated by both serology and molecular ﬁndings were listed here.
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occupationally exposed to NHPs from the large CDC cohort, SFV
infection was found to be much more frequent (3.4%) than
infection by other simian retroviruses such as SIV (0.06%), STLV
(0%) or simian type D retrovirus (0.5%) (Switzer et al., 2004). Such
transmission in personnel from zoos or primate centers was also
recently demonstrated in Gabon and in China (Huang et al., 2012;
Mouinga-Ondeme et al., 2010) (Table 1).
After demonstrating that SFV could infect some laboratory and
zoo workers, the next step was to search for such zoonotic
retroviral infection in a more natural setting. Wolfe et al. pio-
neered that work by investigating the presence of SFVs inindividuals, living in central African forests. They focused their
study on villagers from Cameroon, who reported direct contacts
with blood and/or body ﬂuids from wild non-human primates.
While 10 out of 1099 (1%) individuals from Cameroon, had
antibodies to SFVs, only 3 out of these 10 seropositive persons
had detectable SFV sequences in the DNA extracted from their
PBMCs (Table 2). This study indicated that contacts with NHPs,
which may happen during hunting and butchering can play a role
in the emergence of human retrovirus (Wolfe et al., 2004).
We also developed and extended such studies in different
areas and populations of South Cameroon. After initial studies
demonstrating both a high prevalence and genetic diversity of
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et al., 2004, 2006b), we investigated the presence of SFV infection
in humans living in these regions. We demonstrated the presence
of SFV infection in more than 50 persons (Bantus or Pygmies), the
great majority of them being hunters having been bitten by an
ape (mostly gorilla but also chimpanzee) or a small monkey
(mostly C. nictitans) during hunting activities (Betsem et al., 2011;
Calattini et al., 2007). A recent report from Gabon conﬁrmed such
frequent cross-species transmission in hunters after severe bites
from mostly gorillas (Mouinga-Ondeme et al., 2012) (Table 2).
The situation in Asia is less known. However, recent reports have
already indicated SFV transmission from different macaques species
to temple workers, villagers and pet owners in different countries
form South and Southeast Asia mostly through bites (Jones-Engel
et al., 2005, 2008) (Table 2). Human and macaques sympatry in
Southeast Asia dates back as far as 25.000 years and human-macaque
commensalism is frequent in many monkey temples of these regions
with, each year, a very large number of persons, including tourists, at
risk for macaques bites (Jones-Engel et al., 2006). Indeed, a model has
predicted that in Bali, for every 1000 visitors to monkey temple,
approximately 6 persons will be infected with SFV (Engel et al., 2006).Molecular virology
FV genomic organization
FV are complex retroviruses with genome length ranging from
10 479 bp (Feline FV (Bodem et al., 1998)) to 13249 bp (Simian
FV, chimpanzee strain (Herchenroder et al., 1994)). FV genome
comprises the canonical retroviral gag, pol and env genes, as well
as two additional genes tas and bet that encode proteins having
regulatory functions. It is ﬂanked by two LTRs which contain
elements crucial for FV transcription (Fig. 3).
FV life cycle
FVs have an internal promoter located in the Env gene that
allows basal transcription of the Tas and Bet regulatory proteins
(Campbell et al., 1994). Once produced, the Tas transactivator
activates the internal promoter (IP), giving rise to a positive feedback
loop (Kang et al., 1998). When sufﬁcient amount of Tas is produced,
it can also bind to speciﬁc elements in the LTR promoter, with a
lower afﬁnity than for the IP. Activation of the LTR, which remains
otherwise silent, induces the expression of the Gag, Pol and Env
structural proteins, ultimately leading to the formation of viral
progeny (reviewed in (Rethwilm, 2010)). Tas was also shown to be
a suppressor of RNA silencing (Lecellier et al., 2005).
Unlike Gag proteins from orthoretroviruses which are cleaved
and processed into capsid, matrix and nucleoprotein, FV Gag proteins
are only partially cleaved at the C-terminus generating two species: aSFVcpz
tas
bet
env 3’LTR5’LTR
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14kb
gag pol
Fig. 3. SFV open reading frames and transcription map. A scheme of SFV genome
(chimpanzee strain) and proteins encoded by each mRNA are shown. ORFs are
indicated by boxes. The SFV genome includes the canonical retroviral gag, pol and
env genes and is ﬂanked by two large LTRs which contain elements crucial for FV
transcription. Two additional genes tas and bet encode proteins having regulatory
functions. Indeed, the transactivator Tas binds to the 5’LTR and is responsible for
the transcription of the structural genes gag, pol and env.long and a shorter proteins that only differ by 4 kDa, both being
incorporated in the virion (Enssle et al., 1997). They contain three
Glycine and arginine-rich regions (the GR boxes) important for the
correct FV assembly and the nuclear localization of Gag (Lee and
Linial, 2008; Yu et al., 1996b), the role of which is still not elucidated.
Unlike other retroviral Pol proteins, Pol precursor protein is
synthesized independently of Gag, from a distinct mRNA (Yu et al.,
1996a). This questions the mechanism ensuring Pol packaging
together with Gag. One possible mechanism is that FV genomic
RNA makes the bridge between Gag and Pol (Peters et al., 2005).
Unlike Pol from orthoretroviruses which is cleaved in three mole-
cules, FV Pol is then auto-catalytically cleaved into one molecule
containing the protease and the reverse transcriptase domains, and
another one containing the integrase domain (Pfrepper et al., 1998).
Env protein is cleaved into leader peptide, the surface (SU) and
transmembrane (TM) glycoproteins, but contains an endoplasmic
retention signal which contributes to its site of budding. Indeed,
particles bud from cells primarily through the endoplasmic
reticulum. Moreover, since Gag alone cannot form VLPs (Virus-
like particles), interactions between Env and Gag are essential for
virion budding (reviewed in (Lindemann and Goepfert, 2003)).
The role of the Bet regulatory protein is not well understood.
However, it was shown that Bet can neutralize the cytosine
deaminase APOBEC3G (ApolipoproteinB mRNA-editing enzyme
catalytic polypeptide 3 G) protein (Lochelt et al., 2005), although
it is controversial (Delebecque et al., 2006).
Finally, FVs can also go through a late reverse transcription step,
before the release of FV particles. Thus, unlike orthoretroviruses, FV
particles can contain FV RNA and FV DNA genomes, and interest-
ingly, FV DNA genomes produced in the infected cells can undergo
intra-cellular retrotransposition, with efﬁciency depending upon FV
strain and cell type considered (reviewed in (Rethwilm, 2010)).
Of note, unlike HTLVs, no antisense protein is coded by FV
genome.
FV tropism
FV can infect most cell types in vitro. Heparan sulfates were found
to represent attachment factors. However, FV receptor has not
yet been discovered and is probably ubiquitous. Once productively
infected, cells usually form syncitia with a ‘‘foam-like’’ cytopathic
effect, before cell death occurs (Fig. 4A to D). However, some cell
lines as well as primary cells of the myeloid or lymphoid lineage can
also remain chronically infected (Mikovits et al., 1996; Yu et al.,
1996c). The cellular and viral factors involved in persistence versus
lytic infection are not well understood, but might involve the
regulatory proteins Tas and Bet, with a switch from Tas expression
driving virus particle formation to Tas deletion with a maintained Bet
expression (Saib et al., 1995). In vivo, FV tropism was not intensively
investigated so far, but 2 studies indicate that FV DNA was found in
CD4þ lymphocytes (1/3 AGM and 3/4 chimpanzees), CD8þ lym-
phocytes (2/4 humans, 9/9 AGM and 4/4 chimpanzees), monocytes
(1/4 human and 2/7 AGM and 1/4 chimpanzee) and B cells (1/4
human) (Falcone et al., 1999; von Laer et al., 1996). Moreover, in
NHPs, FV site of replication has been found to be the superﬁcial
epithelial layer of the oral mucosa (Falcone et al., 1999; Murray et al.,
2008, 2006), which explains the mode of transmission of FV by saliva
through bites (Betsem et al., 2011).
FV genetic stability
FV genomes display a high evolutionary conservation among all
the species infected and FV genetic variability within one infected
animal is very low over time (o1% variation) (Schweizer et al.,
1999). This genetic stability might be explained by the long co-
evolution with their host (more than 30 million years) (Switzer
Nucleus
FV antigens
Fig. 4. Observation of foamy virus and foamy viral infected cells. BHK cells were infected with a primary chimpanzee SFV strain (isolated from an SFV-infected hunter,
Betsem et al., 2011) (A) and (B) or by the prototypic strain of SFV (C) and (D) at a multiplicity of infection of 10 and ﬁxed 4 days post-infection. (A) Observation of the SFV-
infected cells was performed under light microscopy and shows a large FV-induced syncytium with a ‘‘foamy’’ aspect. (B) An immunoﬂuorescent staining was performed as
previously described (Calattini et al., 2007). FV antigens are revealed in the green channel and nuclei are stained with DAPI. (C) and (D) Results of the electron microscopy
performed on the FV-infected BHK cells. Sections represent FV viral particles at the proximity of the nucleus (C) or near the microtubule network (D). Scale bars represent
10 mm (A), 3 mm (B) or 300 nm (C) and (D).
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Foamy viruses have even been found in the genomes of sloth
(Katzourakis et al., 2009), coelacanth (Han and Worobey, 2012b)
and Aye Aye (Han and Worobey, 2012a).
Despite this global genetic stability, recombination events
between several circulating FV strains as well as deletions and
mutations have been reported in wild-living chimpanzees (Liu
et al., 2008).
FV restriction in humans
Several groups also reported genetic modiﬁcations including
deleterious mutations in the Bet accessory gene in one SFV-
infected human (Callahan et al., 1999). Some other features were
also reported in humans infected with FVs, although they are
probably not speciﬁc to human infection. This includes deletion in
the U3 sequence of the LTR, which might improve FV replication
at least in vitro (Schmidt et al., 1997). This also includes deletion
in the Tas sequence, which might be linked with the chronicity of
the infection as previously suggested (see above).
However, when looking at FV polymorphism in viruses present
in human PBMCs (5 individuals), we did not ﬁnd striking
differences between those viruses and that present in NHPs,
suggesting that, even decades after primary infection, FV genomes
are still fully replicative (Rua et al., 2012a). This raises the
question of their apparent restriction in humans which might
thus be linked to their immune control. In vitro, FVs are sensed by
human hematopoietic cells and induce the production of the
antiviral cytokines IFN-I (Rua et al., 2012b). In culture systems,
the addition of type I IFN (Regad et al., 2001; Rhodes-Feuillette
et al., 1990; Sabile et al., 1996), or the expression of various IFN-
stimulated genes, including APOBEC3 and tetherin, impair FV replica-
tion (Delebecque et al., 2006; Dietrich et al., 2011; Lochelt et al., 2005;Perkovic et al., 2009; Russell et al., 2005; Xu et al., 2011). It is
tempting to speculate that the type I IFN response is in large part
responsible for the control of viral replication in infected individuals.
In line with these in vitro studies, it was reported once that FV
genomes found in humans displayed few G to A mutations, as if they
were partially sensitive to the action of the APOBEC3G restriction
factors, which are induced by IFN-I (Delebecque et al., 2006). In
addition, neutralizing antibodies are known to inhibit SFV transmis-
sion and infection in rhesus macaques (Williams and Khan, 2010),
indicating that the adaptive immune response may control further
the virus in vivo. Studies are thus needed to understand the role of the
adaptative immune system in FV restriction in humans.Discussion
The recent discovery of HTLV-3/4 and foamy retroviruses in
humans raises important questions, still unanswered, concerning
different aspects of the natural history of these retroviruses (Fig. 5).1) The ﬁrst question concerns the magnitude and the distribution
of these viruses in humans living in areas that are highly
endemic for infected non-human primates.
Concerning foamy viruses, around 100 persons have already
been convincingly reported as infected by SFV (Tables 1 and 2).
Most of them are living in central Africa, especially in villages or
settlements located in the forest area of Cameroon and Gabon.
In most cases, infected persons are men who reported a close
contact, especially a bite from a NHP during hunting activities
(Fig. 6). However, in few cases including some women, the exact
origin of the infecting contact remains yet unknown (Betsem
et al., 2011; Calattini et al., 2007; Wolfe et al., 2004). This
suggests the possibility of viral transmission during handling,
Fig. 6. Common scenes in villages of rural areas of South and East Cameroon showing possible human exposure to simian retroviruses. (A) Full basket of wild-monkey
game for sale. (B) Hunted monkey (C. neglectus) for consumption. (C) Hunted monkey (C. cephus) for sale. (D) Hunter and a monkey (C. nictitans) he just killed. (E) Captive
mandrill (M. leucophaeus) used as a pet.
Fig. 5. Schematic representation of the different steps leading to possible retroviral emergence from non-human primates to Humans. Such viral emergence is a multi-step
process involving mostly viral transmission per se to Humans by different possible contacts with infected body ﬂuids (initial spill-over) and then spread in the human
population. For HTLV-3/4 and simian foamy viruses, the inter-human population diffusion has not been yet demonstrated and the zoonotic strains seems to be mainly
restricted in the few persons having been directly in contact with infected NHPs. This is totally different to the situation with the other human retroviruses of zoonotic
origin as HIV-1 and HTLV-1, which have became largely epidemic and endemic, respectively.
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game. These tasks are frequently performed by women. Future
studies are also necessary to deﬁne SFV prevalence in humansliving in other areas of Africa. In Asia, even if the situation is less
known, presence of SFV have already been clearly reported
in some persons (Huang et al., 2012; Jones-Engel et al., 2005,
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Asia common (Jones-Engel et al., 2006). Thus, SFV infections in
humans are likely to be very prevalent among persons who live
or work near NHPs.
Concerning HTLV-3 and HTLV-4, the only data available so far
were obtained from a series of a few thousand individuals
mostly living in south Cameroon (Calattini et al., 2009, 2011,
2005; Wolfe et al., 2005; Zheng et al., 2010), an area where
STLV-3 strains are endemic in several monkey species. One
could however hypothesize that HTLV-3/4 viruses are also
present (probably at a low prevalence) in other populations
living in other countries of West, Central and East Africa. Indeed,
in such regions; (i) HTLV indeterminate Western blot serologies
are frequent, including some patterns that are quite similar to
those found in HTLV-3 infected persons and (ii) STLV-3 strains
have been reported to be endemic in several monkey species
fromWest (Meertens and Gessain, 2003), Central (Liegeois et al.,
2008; Meertens et al., 2003), and East Africa (Takemura et al.,
2002; Van Dooren et al., 2004). However, studies speciﬁcally
aimed at detecting HTLV-3 and HTLV-4 in such countries have
not been published. We should also keep in mind the very
peculiar epidemiology of HTLV-1 and HTLV-2, with the presence
of high endemic foci, often located nearby large regions with a
low prevalence. This has been well exempliﬁed recently in South
Cameroon for HTLV-2. Indeed, in this large area, HTLV-2 is
nearly absent, except in the Bakola’s Pygmy population
(Mauclere et al., 2011). Such situation which is very probably
linked to a founder effect followed by favorable viral transmis-
sion in a given community, may also happen for HTLV-3 or -4
infections.2) The second question concerns the possibility of inter-human
transmission of those retroviruses.
Based on available data, SFV transmission among humans has
not been yet demonstrated. Indeed, only around 40 family
members (mostly spouses) of men infected by SFV have been
studied and scored negative (Betsem et al., 2011; Callahan et al.,
1999; Heneine et al., 1998; Switzer et al., 2004; Boneva et al.,
2007) suggesting that SFV transmission does not occur fre-
quently through sexual contacts or saliva exposure. The persis-
tence of infectious virus in PBMCs, and the identiﬁcation of
infected blood donor (CDC study conducted in North America
(Boneva et al., 2002)) had raised safety concerns regarding a
potential viral transmission through blood transfusion. These
concerns are supported by recent studies demonstrating that SFV
can be transmitted in macaques through blood transfusion of an
infected donor animal ((Khan and Kumar, 2006) and reviewed in
(Khan, 2009)). Studies are ongoing to search for SFV replication
sites in infected humans (Rua et al., unpublished data).
The HTLV-3/4 situation is probably different. Even if these
viruses originally arose through interspecies transmission from
STLV-3/4 infected monkeys to humans, it is difﬁcult to spec-
ulate on the relative part of the direct acquisition from infected
monkeys versus the acquisition from other infected humans
through sexual activity or breast-feeding. Most HTLV-1/2
infected individuals living in central Africa were very probably
infected through human contacts and not through NHPs inter-
species transmission. Familial studies on larger series of HTLV-
3/4 infected studies are thus required to determine whether
those viruses can be transmitted from humans to humans.3) The third question concerns their possible associated morbid-
ity and mortality in humans.
Concerning SFVs, their apparent lack of pathogenicity in
humans is based on studies conducted on a very limited
number of cases with a short follow-up (Boneva et al., 2007),
and contrasts with the massive in vitro lytic properties of these
viruses both in monkeys and in human cells. The selection biasinherent to the enrolment of mostly healthy persons, in the
few published series limits greatly the ability to identify any
potential acute and/or severe associated diseases. Ongoing
case-control study, based on a larger number of SFV-infected
persons is therefore necessary to shed light on any possible
chronic diseases and/or biological abnormalities associated to
SFV infection in humans. However, we have to keep in mind
that, as for all the diseases associated with HTLV-1, incidence
of disease in an SFV infected person might be very low and
may follow very long latency periods. Thus, more data are
absolutely needed before SFV can be classiﬁed as a non-
pathogenic virus in humans.
Regarding HTLV-3/4, the situation is even more complex, since
only 5 cases (4 HTLV-3 and one HTLV-4) have only been
reported (Calattini et al., 2009, 2011, 2005; Wolfe et al., 2005;
Zheng et al., 2010).
Questions regarding any possible chronic/acute disease and/or
biological abnormality in humans are similar to SFVs with the
necessity of a case-control study based on larger numbers of
HTLV-3/4 positive individuals, with a long term follow-up.
Regarding viral tropism and pathogenicity of STLV-3, colonies
of infected STLV-3 NHP are already available and might allow
to answer to these questions. Alternatively, the use of other
animal models such as humanized-mice might also allow us to
determine the pathogenicity of those viruses.
Finally, another way for determining whether diseases are
associated with these retroviral infections in humans would be to
conduct a speciﬁc study among hospitalized patients, in Africa
(for both SFVs and HTLV-3/4) or in Asia for SFV infection.Conclusion
Hunting wild game, including several non-human primate
species has been performed for millennia, in several areas of the
African continent by different populations. Some of them were
even quite specialized in such hunting activities as all the Hunter-
gatherer groups, including several Pygmies tribes living in Central
Africa. In most cases, bushmeat hunting and related-activities
(butcher, smoked meat, selling, consumption, pets,..) were quite
restricted to remote areas with mostly local meat consumption.
The situation has greatly changed during the last decades due to
several factors. As an example, there has been a tremendous increase
of hunting activities, resulting from a combination of urban demand
for bushmeat, greater access to NHP habitats provided in part by
logging roads, easier accessibility to ﬁre arms, and an increase in
populations living in forest areas, as well as the associated increase in
local food needs. Growing urban populations, expansion of logging
industries and oil and mining companies and even in some cases,
armed conﬂicts have also contributed at different levels to the
increase of bushmeat trade. Interestingly, in a study conducted in
South Cameroon, most SFV-infected persons were relatively young
and have acquired the virus during the last 20 years indicating that
such cross-species transmission is still ongoing (Betsem et al., 2011).
Today, between 3 and 5million tons of bushmeat are eaten each year
(with around 15% originating from NHPs) in Central Africa. There is
an evident lack of economic options of affordable substitutes. Indeed,
bushmeat is around 75% cheaper than domestic meat (Coad et al.,
2010; Karesh and Noble, 2009; Macdonald et al., 2011; Wolfe, 2005).
Several studies have well demonstrated that many if all NHP
species killed in central Africa are endemic for several retroviral
infections including different SIV, STLV and SFV ((Betsem et al.,
2011) and reviewed in (Locatelli and Peeters, 2012; Peeters and
Delaporte, 2012). Thus, in Central Africa, the number of contacts
at risk for retroviral infection between humans and infected
A. Gessain et al. / Virology 435 (2013) 187–199 197NHPs has greatly increased during the last decades opening thus
new possibilities for retroviral emergence in the local human
population.
Finally, it is important to envision the consequence of such
retroviral infection in an immuno-compromised person. Indeed, HIV
is now endemic in many African countries at a relatively high level in
rural and urban adult populations that are now at risk for retroviral
(STLV, SFV, SIV) cross-species transmissions. Such co-infections are
very likely to occur in Central African populations where HIV-1 is
endemic and were in fact already reported (Switzer et al., 2008). The
outcome of an HTLV-3/4 or SFV infection in an immunosuppressed
person is unknown. However, one may expect that such co-infection
may modify (pro)viral load and/or tissue distribution (as shown for
macaques co-infected with SIV and SFV for instance (Murray et al.,
2006)) and thus possibly viral transmission and pathogenicity in the
infected person.
Efforts to reduce the risk of cross-species transmission are thus
necessary to try to better control the potential threat of such
simian retroviruses in humans. Therefore, development of alter-
natives to hunting is necessary locally with all the different
partners living in these areas where interaction with NHPs, and
other games, mostly through hunting is part of the culture and
tradition, as well as related to important economic needs.Acknowledgements
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